With gains of 2.8%, Qiagen was one of the winners on Wall Street today. Its shares are now trading at $46.18 and have logged a -1.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:
-
Qiagen has moved -2.5% over the last year, and the S&P 500 logged a change of -1.4%
-
QGEN has an average analyst rating of buy and is -14.91% away from its mean target price of $54.27 per share
-
Its trailing earnings per share (EPS) is $1.85
-
Qiagen has a trailing 12 month Price to Earnings (P/E) ratio of 25.0 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $2.32 and its forward P/E ratio is 19.9
-
The company has a Price to Book (P/B) ratio of 3.03 in contrast to the S&P 500's average ratio of 2.95
-
Qiagen is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
QGEN has reported YOY quarterly earnings growth of -30.8% and gross profit margins of 0.7%
-
The company has a free cash flow of $447.79 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
-
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.